Uncontrolled Asthma

SAN FRANCISCO — A higher proportion of patients with severe, uncontrolled asthma treated with tezepelumab achieved on-treatment clinical response compared with patients treated with placebo, according to a new NAVIGATOR study analysis.

Adults with high levels of anxiety due to COVID-19 during the first few months of the pandemic were more likely to experience uncontrolled asthma, according to a study published in Annals of Allergy, Asthma & Immunology.

Children with overweight or obesity faced significantly higher odds for dysanapsis and peripheral airway impairment, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Black and Hispanic individuals and those on Medicaid insurance have the highest risk for uncontrolled asthma, researchers reported at the CHEST Annual Meeting.

Dupilumab treatment led to clinical asthma remission in patients with uncontrolled moderate-to-severe asthma with type 2 inflammation, according to a post hoc analysis of the LIBERTY ASTHMA QUEST study.

A survey revealed that many patients with allergy and asthma who use cannabis — including those with uncontrolled asthma — smoke or vape cannabis rather than use edibles or tinctures.

Doubling the inhaled corticosteroid dose and adding umeclidinium to inhaled corticosteroid/long-acting beta agonist in a single-inhaler triple therapy improved outcomes in inadequately controlled asthma, data from the CAPTAIN study show.